Processa Pharmaceuticals Enters Into A Licensing Agreement With Ocuphire Pharma, Inc., For The Development Of RX-3117

Ocuphire Announces Addition to the Russell Microcap® Index

2021 Annual Meeting of Stockholders

Jun 7, 2021 • 4:00pm EDT

KOL Webinar on Nyxol as a Potential New Option for Reversing Pharmacologically Induced Mydriasis

May 26, 2021 • 1:00pm EDT